Accelerating Development of Better PTSD Treatment for Veterans: The VA PTSD Psychopharmacology Initiative (PPI)

| CSR&D Home |

Since 2016, VA Research has been working to support the development of new medication treatments through focused clinical trials under our PTSD Psychopharmacology Initiative (PPI). While there are two FDA approved medications for PTSD (both antidepressants), not everyone successfully tolerates or responds to those medications, and thus our clinical trials program has grown to accommodate multiple ongoing studies (described below).  It is the goal of the PPI to identify, test, and confirm new effective medications that could become available for PTSD treatments.

In this effort we still need investigators to:

1. Evaluate local interest in serving as a performance sites for PTSD medication studies. Researchers who wish to serve as site investigators should notify their Research Office and assist with the completion of the PPI Site Survey.

2. Conduct research on new compounds. We encourage eligible VA investigators who are interested in testing new medications for PTSD in Veterans to apply for funding through the CSR&D Clinical Trials program.  The first step in this process is to submit a Clinical Trial letter of intent.  Instructions and deadlines can be found in Section IV of our Resources For the VA Research Community

The PPI is an integral part of the Clinical Science Research and Development (CSRD) roadmap, Accelerating the Translation of New Medications for Veterans with PTSD. This document illustrates our progress to date as well as future goals related to this important effort.

Questions regarding PPI may be submitted to CLIN-Review@va.gov.

Active/Completed PTSD Medication Studies